Suebpong Tanasanvimon

Bangkok, Thailand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Efficacy and Safety of Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma: A Real-World Multicenter Observational Study.

Efficacy and Safety of Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma: A Real-World Multicenter Observational Study.

Journal: Oncology research

Published: April 01, 2026

Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study.

Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study.

Journal: BMJ oncology

Published: January 24, 2026

The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma.

The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 22, 2025

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma.

Journal: ESMO open

Published: December 02, 2025

Feasibility and Preliminary Effectiveness of the ChulaCancer Mobile Chatbot for Supportive Care of Patients With Breast or Colorectal Cancer Receiving Chemotherapy: Pilot Randomized Controlled Trial.

Feasibility and Preliminary Effectiveness of the ChulaCancer Mobile Chatbot for Supportive Care of Patients With Breast or Colorectal Cancer Receiving Chemotherapy: Pilot Randomized Controlled Trial.

Journal: JMIR formative research

Published: November 20, 2025

Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study.

Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study.

Journal: PloS one

Published: August 17, 2025

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer.

Journal: ESMO open

Published: June 03, 2025

The Double-Blind Placebo-Controlled Study Comparing Upfront and Subsequent Netupitant in Addition to Olanzapine-Containing Regimen for Prevention of High-Dose Cisplatin-Induced Nausea/Vomiting.

The Double-Blind Placebo-Controlled Study Comparing Upfront and Subsequent Netupitant in Addition to Olanzapine-Containing Regimen for Prevention of High-Dose Cisplatin-Induced Nausea/Vomiting.

Journal: Asia-Pacific journal of clinical oncology

Published: May 26, 2025

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.

Journal: Journal of hepatology

Published: January 27, 2025

Corrigendum to "Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer": [ESMO Open 9 (2024) 103647].

Corrigendum to "Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer": [ESMO Open 9 (2024) 103647].

Journal: ESMO open

Published: January 26, 2025

One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequency ablation.

One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequency ablation.

Journal: Gastrointestinal endoscopy

Published: December 19, 2024

Overall survival with frontline vs subsequent anti-epidermal growth factor receptor therapies in unresectable, RAS/BRAF wild-type, left-sided metastatic colorectal cancer.

Overall survival with frontline vs subsequent anti-epidermal growth factor receptor therapies in unresectable, RAS/BRAF wild-type, left-sided metastatic colorectal cancer.

Journal: World journal of clinical oncology

Published: October 07, 2024

Showing 1-12 of 41

Last Updated: 09/26/2026